Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum AB's revenue for the
three
months ended in Jun. 2026 was $824 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $3,266 Mil.
Swedish Orphan Biovitrum AB's Revenue per Share for the
three
months ended in Jun. 2026 was $2.35.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $9.36.
Good Sign:
Swedish Orphan Biovitrum AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Swedish Orphan Biovitrum AB was 12.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 19.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Revenue per Share Growth Rate was 40.90% per year. The lowest was -31.70% per year. And the median was 11.50% per year.
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Swedish Orphan Biovitrum AB Revenue Related Terms
Swedish Orphan Biovitrum AB Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Revenue distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,266 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (BIOVF) has a Revenue of $3,266 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Revenue too high?
Swedish Orphan Biovitrum AB's current Revenue is $3,266 Mil. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Revenue compare to ZTS?
Swedish Orphan Biovitrum AB's Revenue of $3,266 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Revenue is $3,266 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Modestly Overvalued. The stock's GF Value™ is $37.33, compared to a current price of $48.21 — trading 29.1% above its estimated fair value. The current Revenue is $3,266 Mil. Swedish Orphan Biovitrum AB's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current Revenue is $3,266 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $48.21 is trading 29.1% above its estimated GF Value™ of $37.33.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for BIOVF:
Revenue: $3,266 Mil
GF Value™: $37.33 vs. price of $48.21 (29.1% above fair value)
No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score
Get the complete analysis for BIOVF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOVF has been successfully added to your 
